These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31439675)

  • 1. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
    Moreau P; Sonneveld P; Boccadoro M; Cook G; Mateos MV; Nahi H; Goldschmidt H; Dimopoulos MA; Lucio P; Bladé J; Delforge M; Hajek R; Ludwig H; Facon T; Miguel JFS; Einsele H
    Haematologica; 2019 Dec; 104(12):2358-2360. PubMed ID: 31439675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
    García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
    Front Immunol; 2020; 11():1128. PubMed ID: 32582204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell therapy for multiple myeloma.
    Hosen N
    Int J Hematol; 2020 Apr; 111(4):530-534. PubMed ID: 31981097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Future therapeutic strategies for multiple myeloma].
    Ishida T
    Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.
    Jindal V; Khoury J; Gupta R; Jaiyesimi I
    Am J Clin Oncol; 2020 May; 43(5):371-377. PubMed ID: 31990758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Myeloma: The CAR T-cell Therapy Landscape.
    Cancer Discov; 2020 Feb; 10(2):OF6. PubMed ID: 31915196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
    Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M
    Haematologica; 2021 Aug; 106(8):2054-2065. PubMed ID: 33792221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical development of CAR-T therapy for refractory multiple myeloma].
    Ohmine K
    Rinsho Ketsueki; 2018; 59(8):1058-1065. PubMed ID: 30185706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
    Cowan AJ; Tuazon SA; Portuguese AJ; Green DJ
    Cancer J; 2021 Mar-Apr 01; 27(2):112-118. PubMed ID: 33750070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.
    George LL; Deshpande SR; Cortese MJ; Kendall EK; Chattaraj A; Shah Z; Zhao J; Anwer F
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):741-751. PubMed ID: 34253497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.